Gilead challenges US govt patents on HIV drug Truvada
22-08-2019
Generic of Gilead’s HIV pre-exposure drug coming to market in 2020
09-05-2019
Ascannio / Shutterstock.com
Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Gilead, HIV, generics, lawsuit, investors, Truvada, drug manufacturer, US District Court for the Northern District of California, Cipla, PrEP, J&J
